Month: July 2020

At the American Society of Retina Specialists meeting, our team & colleagues had…

At the American Society of Retina Specialists meeting, our team & colleagues had numerous presentations on #retina clinical science as well as #suprachoroidal delivery of tyrosine kinase inhibitor, complement Inhibitor & corticosteroid. #biotech #medicine #clinicalresearch Source by Thomas Ciulla, MD, MBA Return to main website.

RT @Ophthalmologymg: Update on gene therapy: Ocular gene therapy research has sh…

RT @Ophthalmologymg: Update on gene therapy: Ocular gene therapy research has shown tremendous growth over recent years. This article discu… Source by Thomas Ciulla, MD, MBA Return to main website.

Our study has generated much interest in #Luxturna #genetherapy #healtheconomics…


Our study has generated much interest in #Luxturna #genetherapy #healtheconomics: Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Retinal Disease https://t.co/3DeMpzCgRq via @JAMAOphth part of @JAMANetwork


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: Recently co-authored “Update on gene therapy: A discussion o…

RT @ThomasCiullaMD: Recently co-authored “Update on gene therapy: A discussion of strategies, optimization, alternatives and administration… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @VestrumHealth: …

RT @VestrumHealth: https://t.co/On63W7xSpL Source by Thomas Ciulla, MD, MBA Return to main website.

RT @OTEurope: How DME patients may fare differently in ‘real world’ versus trial…


RT @OTEurope: How DME patients may fare differently in ‘real world’ versus trials https://t.co/37omb0jo7P https://t.co/mWVlEnaB0Q


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ViralKansaraPhD: I had the privilege of being a part of the research where m…

RT @ViralKansaraPhD: I had the privilege of being a part of the research where my colleagues and I examined the “biofactory approach” in #G… Source by Thomas Ciulla, MD, MBA Return to main website.

Recently co-authored “Update on gene therapy: A discussion of strategies, optimi…

Recently co-authored “Update on gene therapy: A discussion of strategies, optimization, alternatives and administration”, in Ophthalmology Management’s “Future of Retinal Care” issue… #genetherapy #ophthalmology #amd #diabetes #retina #eyes https://t.co/bXNWa4p7G0 Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinalPhys: Anti-VEGF Therapy in Macular Edema Due to Retinal Vein Occlusio…


RT @RetinalPhys: Anti-VEGF Therapy in Macular Edema Due to Retinal Vein Occlusion: Real-world outcomes differ from those of clinical trials…


Source by Thomas Ciulla, MD, MBA

Return to main website.

Just authored this @RetinalPhys​ article highlighting our #research on a leading…

Just authored this @RetinalPhys​ article highlighting our #research on a leading cause of #vision loss. More effective and longer acting #treatments are needed! Retinal Physician – Anti-VEGF Therapy in Macular Edema Due to Retinal Vein Occlusion https://t.co/tR4b3mO078 Source by Thomas Ciulla, MD, MBA Return to […]